[Funding alert] London-based ThinkSono Secures €2.4 Million in Funding

Leading the most recent round was id4 Ventures, with participation from several well-known angel investors and vascular surgery physicians, as well as Brandenburg Kapital, Calm Storm Ventures, Dubai Angel Investors, CrowdCube, and Cur8 Capital. To date, the company has raised about £5 million.

The company's goal of revolutionizing medical imaging technology and improving patient care globally will be furthered by this funding. ThinkSono announced that its flagship product, the ThinkSono Guidance system, has received the Class IIb CE certification in conjunction with this funding.

Read also - Osnabrück-based NeoTaste Secures €15.1 Million in Series A Extension Funding

By allowing non-ultrasound educated healthcare workers to screen patients for blood clots (DVT) and forward the results for certified physician assessment, ThinkSono Guidance software enhances the clinical pathway. To put things in perspective, DVT is a major global cause of avoidable hospital deaths.

This accomplishment solidifies it's position as a frontrunner in the AI ultrasound guided technology market by highlighting the company's dedication to providing innovative AI solutions that adhere to strict quality and safety requirements. Since its founding in 2016, ThinkSono has collaborated with hospitals in Germany, Greece, the UK, and other parts of Europe.

In addition, it is thrilled to declare strategic alliances with NYU Langone Health and Temple Health, two esteemed American healthcare organizations, in order to forward its application for FDA approval of its ground-breaking products.

Working together with these prestigious institutions will hasten the regulatory approval procedure and make it easier to introduce it's ground-breaking technology into the American healthcare industry.

Pouad Al Noor, CEO and Founder of ThinkSono said, “We are thrilled to announce this significant funding milestone and the achievement of key regulatory milestones for our ThinkSono Guidance system, This funding will enable us to further advance our mission of revolutionizing medical imaging technology, while our partnerships with NYU Langone Health and Temple Health underscore our commitment to delivering innovative solutions that ultimately improve patient outcomes.”

ThinkSono’s CMO and Professor of Emergency Medicine, Michael Blaivas said, “The inability to quickly and timely rule out lower extremity DVT has been the bane of healthcare providers for decades. This problem impacts settings from office practices, clinics, emergency departments, hospital floors to intensive care units and more, ThinkSono’s technology addresses this problem directly and has the potential to significantly improve patient care across Europe and beyond.”

About ThinkSono

ThinkSono is dedicated to lowering the obstacles in the way of everyone having access to ultrasounds. Their goal is for every healthcare provider to be able to safely do ultrasound diagnosis at the point of treatment. Any healthcare provider may identify deep vein thrombosis (DVT) at the point of treatment in as little as five minutes with their initial application, AutoDVT.

Read also - Vienna-based Necture Secures €7 Million in Series A Round Funding